Cencora, Inc. (NYSE:COR) Shares Sold by Wealthfront Advisers LLC

Wealthfront Advisers LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 22.6% during the 4th quarter, Holdings Channel reports. The fund owned 14,239 shares of the company’s stock after selling 4,150 shares during the quarter. Wealthfront Advisers LLC’s holdings in Cencora were worth $3,199,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Swedbank AB lifted its stake in Cencora by 2.3% during the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock worth $313,863,000 after purchasing an additional 31,104 shares during the last quarter. United Bank grew its holdings in shares of Cencora by 4.2% during the third quarter. United Bank now owns 5,601 shares of the company’s stock worth $1,261,000 after purchasing an additional 225 shares during the last quarter. Assetmark Inc. increased its position in shares of Cencora by 33.8% during the third quarter. Assetmark Inc. now owns 2,536 shares of the company’s stock worth $571,000 after purchasing an additional 641 shares in the last quarter. Ashton Thomas Securities LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at about $41,000. Finally, GSA Capital Partners LLP purchased a new position in Cencora during the 3rd quarter worth approximately $1,137,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on COR. JPMorgan Chase & Co. increased their price objective on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a report on Friday, January 24th. Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price for the company. Wells Fargo & Company boosted their price target on Cencora from $237.00 to $251.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 29th. Finally, StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $277.90.

Cencora Stock Performance

Shares of COR stock opened at $255.64 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The stock has a 50 day simple moving average of $247.01 and a 200-day simple moving average of $238.93. The company has a market cap of $49.57 billion, a price-to-earnings ratio of 36.36, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $263.70.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is 31.29%.

Insider Buying and Selling

In other news, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now directly owns 15,374 shares in the company, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Lazarus Krikorian sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the sale, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 13,648 shares of company stock valued at $3,382,462. Corporate insiders own 10.80% of the company’s stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.